Bertelsmann Investments Expands cormeo with Acquisition of AI Content Pioneer Docuvera

Bertelsmann Investments is expanding its footprint in Pharma Tech with the full acquisition of Docuvera, a leading provider of AI-driven structured content authoring solutions for the Life Sciences industry. The deal is part of the group’s strategic growth initiative, Bertelsmann Next.

Docuvera joins the cormeo portfolio, which already includes EXTEDO and Rote Liste. This consolidation strengthens cormeo’s ambition to offer an end-to-end solution for regulated information lifecycle management across the Life Sciences value chain.

“The acquisition of Docuvera is a perfect fit for cormeo and underlines our strong commitment to Pharma Tech innovation,” says Deniz Pielsticker, CFO of Bertelsmann Investments. As part of Bertelsmann Next, cormeo will continue to receive support through both organic development and targeted acquisitions.

Docuvera’s structured content and AI technology streamline the entire content lifecycle – from authoring and review to approval and multilingual publishing. This enhances operational efficiency, reduces regulatory risks, and shortens time to market for Life Sciences organizations.

Peter Koop, CEO of cormeo, states: “We are thrilled to welcome Docuvera into the cormeo family. This strategic move not only broadens our solution portfolio but accelerates our mission to deliver cutting-edge tools for the evolving needs of the Life Sciences sector.” Tobias Beer, COO of cormeo and advisory board member of Docuvera, adds: “This acquisition is a key step in building a seamless end-to-end content lifecycle platform. With Docuvera’s expertise in structured content and AI, we can help our clients boost efficiency, improve traceability, and ensure compliance.” Stephen Owens, the newly appointed CEO of Docuvera, says: “We are excited to become a full member of the cormeo portfolio. Together, we will continue pushing the boundaries of content innovation and deliver transformative solutions to customers navigating an increasingly digital world.”

This move is a continuation of Bertelsmann’s strategic push into emerging technologies in Pharma Tech, HR Tech, and Mobile Ad Tech – empowering companies to transform digitally while improving patient care and regulatory excellence.